WebbAmendment Number One to License Agreement, dated as of July 20, 2024, by and among Gritstone Oncology, Inc., Arbutus Biopharma Corporation and its subsidiary Protiva … Webb1 Patent Owner explains that Protiva Biotherapeutics, Inc., identified as the patent owner in IPR2024-00680 and IPR2024-00739, previously “existed as a wholly-owned subsidiary of …
Imagine That IP Law Blog Volpe Koenig: Volpe Koenig
Webb11 apr. 2024 · On appeal, Arbutus Biopharma Corporation challenges the Board’s anticipation finding. We affirm. BACKGROUND Protiva Biotherapeutics, once a wholly owned subsidiary of—and is now amalgamated into—Appellant Arbutus Biopharma Corporation (“Arbutus”), owned U.S. Patent No. 9,404,127 (the “’127 patent”). Webb1 juni 2008 · Protiva is now a wholly-owned subsidiary of Tekmira. Pursuant to the private placement, Tekmira has issued approximately 2.1 million shares to each of Alnylam and … infocus projector keeps auto resizing
Tekmira Pharmaceuticals and Protiva Biotherapeutics ...
Webb22 juli 2015 · Arbutus Biopharma acquired Protiva Biotherapeutics for $22,800,000 . Discover more acquisitions . Funding Round • Jul 6, 2007. Protiva Biotherapeutics raised $3,300,000 / Series Unknown from BDC Venture Capital and 3 other investors . Discover more funding rounds . Webb17 dec. 2024 · Acuitas had itself acquired a license to this technology from Arbutus Biopharma (which was formerly known as Protiva Biotherapeutics.) Arbutus … Webb3 dec. 2024 · See Moderna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc., IPR2024-00739, 2024 Pat. App. LEXIS 13612 (Sept. 11, 2024) (“Board Decision”). Arbutus Biopharma Corporation (“Arbutus”)1 cross-appeals from the Board’s decision holding that claims 1–6, 9, 12, and 14–15 are unpatentable as anticipated. infocus projector lamp hours